X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types of solid tumor cancer.
Lead Product(s): Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Elevar Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
HQP1351 (olverembatinib) is a novel third-generation BCR-ABL inhibitor that can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation, for the treatment of patients with CML intolerant/resistant to at least two TKIs).
Lead Product(s): Olverembatinib
Therapeutic Area: Oncology Product Name: HQP1351
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Ascentage Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
The agreement names Tanner Pharma Group as the exclusive provider of Oxervate (cenegermin) in countries outside of the United States, Canada, Italy, China and CIS countries (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, and Uzbekistan).
Lead Product(s): Cenegermin
Therapeutic Area: Ophthalmology Product Name: Oxervate
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dompe Farmaceutici
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 30, 2020
Details:
Under the terms of the agreement, Tanner will be the exclusive supplier of Apealea to health care providers outside of the U.S. on a named patient basis in countries where Apealea is not yet commercially available.
Lead Product(s): Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Apealea
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Elevar Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 27, 2020
Details:
Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.
Lead Product(s): Clozapine
Therapeutic Area: Psychiatry/Psychology Product Name: Versacloz
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tasmanian Alkaloids Pty Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
